2023-05-18 21:35:33
A study of obese young people showed that 45% of them were no longer considered obese following using Ozempic for 15 months. The research was published on Wednesday (17/5) by the scientific journal Obesity and showed that the weekly use of an injectable dose of 2.4mg per week of semaglutide was enough to guarantee that 75% of them fell into at least one category of your BMI (body mass index) levels.
“These results show that the medication is very efficient in the treatment of obesity. Historically, we have never seen such effective results other than in bariatric surgery treatments. Now we have to work to make it accessible,” said study lead Aaron Kelly in a press release.
The research was done by Kelly and other professors at the University of Minnesota with adolescents aged 12 to 18 who were obese. They were evenly split in terms of their BMI level. A healthy weight is defined as having a BMI between 18 and 24:
- 69 participants had grade 3 obesity, with a BMI greater than 40;
- 69 had grade 2 obesity, with a BMI between 35 and 39;
- 62 had level 1 obesity, BMI between 30 and 34.
The adolescents who participated in the study were divided into two groups, one receiving the medicine and the other a placebo. In addition to follow-up exams during the 68 weeks of the study, they were instructed to follow a healthier lifestyle. Even so, among young people who did not receive the medicine, the rate of those who managed to stop being obese was three times lower.
The study even points out that girls who used Ozempic had even better results. However, as the study was not initially designed to have a division of results by gender, they advise that a new research be carried out to test this evidence. Younger teens and those with lower BMIs also had above-average responses.
Get news from metropolises on your Telegram and stay on top of everything! Just access the channel: https://t.me/metropolesurgente
1684455611
#Ozempic #removed #young #people #obesity